MeiraGTx reports Q3 2026 results, sets bota-vec filing timeline
MeiraGTx plans to submit an EU marketing application for bota-vec in December 2026 and a U.S. BLA in early 2027, with a Parkinson's disease Phase 3 study targeted to start in Q1 2027.
SEC filing